Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Imugene ( (AU:IMU) ) has provided an update.
Imugene Limited has announced an Extraordinary General Meeting scheduled for August 20, 2025, to be held both in-person in Sydney and online via Zoom. This meeting is significant for shareholders as it provides an opportunity to engage in the company’s strategic decisions and vote on key issues, reflecting Imugene’s commitment to maintaining transparent and inclusive governance practices.
The most recent analyst rating on (AU:IMU) stock is a Buy with a A$0.42 price target. To see the full list of analyst forecasts on Imugene stock, see the AU:IMU Stock Forecast page.
More about Imugene
Imugene Limited is a biotechnology company focused on the development of novel therapies for cancer treatment. The company specializes in immuno-oncology, aiming to harness the immune system to fight cancer, and is actively involved in advancing its pipeline of cancer immunotherapies.
YTD Price Performance: -70.19%
Average Trading Volume: 617,700
Technical Sentiment Signal: Sell
Current Market Cap: A$82.4M
See more insights into IMU stock on TipRanks’ Stock Analysis page.